Thermo Fisher Scientific Human Noggin Recombinant Protein

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

Immunohistochemistry (IHC)

Assay-dependent

-

ELISA (ELISA)

Assay-dependent

-

Functional Assay (Functional)

Assay-dependent

-

Control (Ctrl)

Assay-dependent

-

Product Specifications

Species

Human

Expression System

E. coli

Amino acid sequence

MQHYLHIRPA PSDNLPLVDL IEHPDPIFDP KEKDLNETLL RSLLGGHYDP GFMATSPPED RPGGGGGAAG GAEDLAELDQ LLRQRPSGAM PSEIKGLEFS EGLAQGKKQR LSKKLRRKLQ MWLWSQTFCP VLYAWNDLGS RFWPRYVKVG SCFSKRSCSV PEGMVCKPSK SVHLTVLRWR CQRRGGQRCG WIPIQYPIIS ECKCSC

Molecular weight

46.2 kDa

Class

Recombinant

Type

Protein

Purity

>95% by SDS-PAGE

Endotoxin concentration

<0.1 ng/µg

Activity

ED50 < 3 ng/mL; determined by the dose-depdent inhibition of alkaline phosphatase production induced by BMP-4 (5 ng/mL) in ATDC-5 chondrogenic cells.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Wet ice (domestic); Wet or Dry ice (international)

Product Specific Information

Carrier-Free

Reconstitution: Centrifuge the vial briefly, before opening to bring the contents to the bottom. Reconstitute the lyophilized protein in 10 mM acetic acid to a concentration of 0.1-1.0 mg/mL. Apportion the reconstituted protein into working aliquots and store at ≤-20°C. Make any further dilutions of the reconstituted protein in appropriate buffered solution containing a carrier protein, such as 0.1% HSA or BSA.

Storage: The lyophilized protein is stable at room temperature for 3 weeks. Store at -20°C, preferably desiccated. Upon reconstitution, apportion into working aliquots and store at 4°C for 2-7 days, or at -20°C. Avoid repeated freeze-thaw cycles.

Target Information

Noggin is involved in numerous developmental processes, such as neural tube fusion and joint formation. The morphogenesis of organs is initiated by a downgrowth from a layer of epithelial stem cells. This process is achieved through the receipt of signals from 1) a WNT protein (WNT3A) to stabilize beta-catenin; and 2) Noggin, which is a bone morphogenetic protein inhibitor. Noggin mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) have been identified, which have multiple joint fusion as their principal defect.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.